Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-5.08%
$142.13
0% positive prob.
5-Day Prediction
-8.04%
$137.70
0% positive prob.
20-Day Prediction
-4.65%
$142.78
0% positive prob.
SEC 8-K filings with transcript text
Feb 19, 2026 · 100% conf.
1D
-5.08%
$142.13
Act: +4.87%
5D
-8.04%
$137.70
Act: +0.72%
20D
-4.65%
$142.78
icui-20260219falseICU MEDICAL INC/DE000088398400008839842026-02-192026-02-19
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 19, 2026
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 19, 2026, ICU Medical, Inc. issued a press release announcing its financial results for the fourth quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated February 19, 2026 announcing ICU Medical, Inc.'s fourth quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 19, 2026 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
Nov 6, 2025
icui-20251106falseICU MEDICAL INC/DE000088398400008839842025-11-062025-11-06
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 6, 2025
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On November 6, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the third quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated November 6, 2025 announcing ICU Medical, Inc.'s third quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
Aug 7, 2025
icui-20250807falseICU MEDICAL INC/DE000088398400008839842025-08-072025-08-07
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 7, 2025
(Exact name of registrant as specified in its charter)
Delaware001-3463433-0022692 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
951 Calle Amanecer,San Clemente,California92673 (Address of principal executive offices)(Zip Code)
(949) 366-2183 Registrant's telephone number, including area code
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC (Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On August 7, 2025, ICU Medical, Inc. issued a press release announcing its financial results for the second quarter of 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in Item 2.02 by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press release, dated August 7, 2025 announcing ICU Medical, Inc.'s second quarter 2025 earnings. 104Cover Page Interactive Data File (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2025 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer
This page provides ICU Medical Inc. (ICUI) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ICUI's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.